|
|
||||||||
Depts of 1 Anaesthesiology and the Intensive Care Unit, 2 Physiology and 3 Paediatrics, Faculty of Medicine, University of Mie, Edobashi, Tsu, Mie, Japan
CORRESPONDENCE: K. Maruyama, Dept of Anaesthesiology, Mie University School of Medicine, 2-174, Edobashi, Tsu, Mie, Japan, 514-8507. Fax: 81 592315227. E-mail: k-maru@clin.medic.mie-u.ac.jp
Keywords: hypoxia, nitric oxide, pulmonary hypertension, vascular remodelling
Received: June 1, 2001
Accepted January 14, 2002
This study was supported in part by Grants-In-Aid for Scientific Research 09470326, 12470319, and 13877256 from the Japanese Ministry of Education, Science and Culture, and a Grant for Paediatric Research from the Ministry of Health and Welfare.
| Abstract |
|---|
|
|
|---|
Rats were exposed to chronic hypobaric hypoxia (air at 50.5 kPa (380 mmHg), 10% oxygen, for 529 days) to induce chronic pulmonary hypertension (PH) with pulmonary vascular structural changes. After the chronic hypoxic exposure, the rats had an indwelling pulmonary artery catheter inserted and changes in mPAP with NO were correlated to morphometrical analysis of pulmonary vascular changes.
All concentrations of inhaled NO (0.12.0 parts per million) reduced mPAP with a similar per cent reduction from baseline mPAP in PH rats, while no changes were observed in control rats. During NO inhalation in PH rats, the absolute value of the decrease in mPAP, but not per cent reduction in mPAP, significantly correlated with baseline mPAP, the percentage of muscularised arteries at the alveolar wall level and at the alveolar duct level, and the per cent medial wall thickness of muscularised arteries.
In the chronic hypoxic pulmonary hypertension model, the severity of pulmonary vascular remodelling did not alter the reactivity of the pulmonary arteries to nitric oxide and might, in part, determine the magnitude of nitric-oxide induced absolute reduction in mean pulmonary artery pressure.
In all conditions causing pulmonary hypertension (PH), vascular changes include new muscularisation of normally non-muscular peripheral pulmonary arteries and medial muscle hypertrophy of normally muscular arteries. Abnormal muscular pulmonary vasculature might have a heightened reactivity 1, 2, which may explain the effect of nitric oxide (NO) inhalation in hypertensive pulmonary disease, because NO dilates constricted pulmonary vasculature. Although inhaled NO can dilate these structurally-remodelled pulmonary arteries, the degree of response to inhaled NO was quite variable in patients with congenital heart disease 1, primary pulmonary hypertension (PPH) 3, limited scleroderma and isolated PH 4 and severe acute respiratory distress syndrome (ARDS) 5. The differences in severity of pulmonary vascular structural changes might explain the differences in inhaled NO-induced reduction in pulmonary artery pressure (PAP) among patients.
Chronic hypoxia induces PH and hypertensive pulmonary vascular changes in rats 68. With increasing exposure to hypoxia, there is a progressive increase in the severity of the hypertensive pulmonary vascular changes 7. These findings allowed the authors to make a rat model of experimentally different degrees of PH and hypertensive pulmonary vascular changes. To determine the relationship between the hypertensive pulmonary vascular changes and response to inhaled NO, NO inhalation was carried out in a rat model of chronic PH induced by chronic hypoxic exposure of varying durations. Quantitative morphometrical analysis was applied to determine the severity of hypertensive pulmonary vasculature 810. Low-dose NO inhalation
2 parts per million (ppm) was chosen because a lower dose is favourable to minimise any possible toxicity.
| Materials and methods |
|---|
|
|
|---|
|
| (001) |
|
| (002) |
Nitric oxide exposure chamber
NO was obtained from Sumitomo Seika (Chiba, Japan) as a mixture of 89.1 ppm in pure N2. This mixture was introduced into the tube connected to a plastic exposure chamber (
2 L capacity), in which 3 L·min1 constant airflow was developed. The constant airflow was obtained with an air compressor (0.4 OP-7S; Hitachi, Tokyo, Japan) and flow meter. Thus, before NO was introduced into the exposure chamber, the gas was diluted in the upstream of the chamber with fresh air and the oxidation of NO to NO2 in the exposure chamber was avoided as far as possible. The NO concentration in the chamber was measured using a chemiluminescence analyser (CLA-510SS; Horiba, Kyoto, Japan). The limitations of resolution of the chemiluminescence analyser depended on the selected range of measurement: 0.01 ppm for a range of 0l ppm and 0.1 ppm for 010 ppm. The pressure gauge attached to the NO and N2 cylinder was adjusted to obtain the final desired NO concentration in the exposure chamber.
Preparation of lung tissue for structural analysis
After the haemodynamic measurement, the rats were mechanically ventilated through a tracheotomy under pentobarbital sodium anaesthesia. A midline sternotomy was performed to expose the heart and lungs. A blood sample for the haematocrit was obtained from the heart. The main pulmonary artery was cannulated with polyethylene tubing (SP-110; Natsume, Tokyo, Japan) and perfused with saline at a pressure of 20 cmH2O to clear the blood. The pulmonary artery was then injected with a hot (60°C) radiopaque barium-gelatin mixture at a pressure of 100 cmH2O, until snowflakes were obtained on the surface of the lung. The pulmonary artery cannula was clamped and the heart and lungs were removed en bloc. The lung was distended and fixed by perfusion through the tracheal tube with 10% formalin at a pressure of 36 cmH20 for 72 h. A block of tissue obtained from the midsection of the left lung parallel to the hilum was processed for light microscopy by paraffin embedding. Sections were stained for elastin by the Van Gieson method. The right ventricle (RV) of the heart was dissected from the left ventricle plus septum (LV+S) and weighed separately. The ratio of RV/(LV+S) was calculated.
Light microscopy slides were analysed using techniques described previously 810. All barium-filled arteries in each tissue section were examined at a magnification of x400, for an average of 320 arteries·section1 (172502 arteries·section1). Each artery was first identified, according to its accompanying airway, as being related to a terminal bronchiolus, respiratory bronchiolus, alveolar duct or alveolar wall. Each artery was also identified as being one of two structural types: muscularised (muscular, with a complete medial coat of muscle or partially muscular, with an incomplete coat, only a crescent of muscle being present), and nonmuscular (no muscle apparent). The percentages of muscularised arteries at the alveolar wall (%AW) and duct (%AD) level were calculated. For all the muscular arteries between 100 µm and 200 µm in diameter (433 arteries were found per section), usually accompanied with a terminal or respiratory bronchiolus, the wall thickness of the media (distance between external and internal elastic laminae) was measured along the shortest curvature, and the per cent medial wall thickness (%MWT) was calculated 8.
Morphometrical analyses were performed without previous knowledge of hypoxic exposure durations, baseline PAP and responses to NO inhalation. Only after completion of independent morphometric analysis of all specimens were correlations made with the hypoxic exposure durations and the PAP measurements.
Statistical analysis
All values are presented as mean±sem. Relationships between hypoxic exposure period and mPAP, RV/LV+S, %AW, %AD, and %MWT were analysed using linear regression analysis. Analysis of variance (ANOVA) for repeated measures was used to analyse mPAP with and without NO inhalation. Concentration-dependent effects of NO on per cent reduction in mPAP were analysed by one-way ANOVA followed by Scheffe test. Relationships between NO-induced changes in mPAP and morphological parameters (%AW, %AD and %MWT) were analysed using linear regression analysis. A p-value of <0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
Exposure to chronic hypoxia was associated with a significant increase in the level of mPAP, RV/(LV+S), %AW, %AD, %MWT and haematocrit. With increasing exposure period to hypoxia, mPAP, RV/(LV+S), %AW, %AD, %MWT and haematocrit increased in severity. There was significant positive correlation between mPAP and RV/(LV+S) (r=0.66, p<0.0001), %AW (r=0.81, p<0.0001), %AD (r=0.81, p<0.0001), and %MWT (r=0.73, p<0.0001).
Nitric oxide inhalation
Short-term NO inhalation significantly reduced mPAP in PH rats exposed to hypoxia for 5 days (n=12), 10 days (n=6), 1120 days (n=9) and 2129 days (n=5) at all concentrations from the smallest concentration of 0.1 ppm, but not in control rats (repeated measures of ANOVA) (fig. 1
). The per cent reductions in mPAP were not significantly different among these four experimental groups at each concentration of inhaled NO, so values from all rats at the same inhaled concentration were combined to determine the dose-dependent effect of inhaled NO (0.1, 0.25, 0.5, 0.75, 1.0, 1.5 and 2.0 ppm) on per cent reduction from baseline mPAP. There was no significant dose dependency of inhaled NO concentration on per cent reduction in mPAP in the range between 0.12.0 ppm (ANOVA), so that the absolute value of the reduction in mPAP during NO inhalation in each rat was expressed as the average value of the changes at all concentrations of NO. The absolute value of the decrease in mPAP during NO inhalation significantly correlated with the baseline mPAP (r=0.58, p=0.0005) (fig. 2
).
|
|
Aortic pressure
There was no change in aortic pressure with 5 ppm NO inhalation in PH rats (n=4) (12.40±0.98 kPa (93.3±7.4 mmHg) without NO; 12.40±0.88 kPa (93.3±6.6 mmHg) with NO).
| Discussion |
|---|
|
|
|---|
Pressure is dependent on blood flow and vascular resistance. Although PAP depends upon cardiac output, measurement of cardiac output in conscious rat during NO inhalation is difficult. The authors measured mSAP through the indwelling aortic catheter during and after the NO inhalation at 5 ppm in some rats. Because no significant changes in mSAP during NO inhalation were found and because inhaled NO is a selective pulmonary vasodilator 1, 35, it was assumed that the cardiac output remained unaffected with NO inhalation, even though it was not measured in the present experiment. The previous study in patients with PH also reported no changes in the values of cardiac output and SAP during NO inhalation 11.
Inhaled NO significantly reduced mPAP in PH rats, but not in normal rats. In normal rats, pulmonary vasculature might be maximally dilated. The absolute value of reduction in mPAP and per cent reduction from baseline mPAP was less than that reported in earlier clinical reports 12, 13, suggesting that the reversible component plays a minor role in the increase in PAP in chronic hypoxic PH. Fixed vascular structural changes might contribute to the increase in mPAP. Since NO inhalation was performed in room air more than 24 h after weaning from chronic hypoxic exposure, there should be little hypoxic pulmonary vasoconstriction. Although the intrinsic tone (reversible component) was small, this component was significantly correlated with the vascular changes. Inhaled NO reduced vascular tone that might be intrinsic in hypertensive pulmonary vasculature.
Generally, a polycythaemia follows chronic hypoxic exposure and plays an important role in hypoxic PH in rats and humans. The authors measured the haematocrit value and found that there was a progressive increase in haematocrit with increasing exposure to hypoxia (0 days: 41.5%; 10 days: 58.0%; 1120 days: 60.1%; and 2129 days: 68.6%). It was also found that there were similar percentage reductions in mPAP during NO inhalation from 0.12.0 ppm. It was therefore speculated that polycythaemia did not decrease the relaxant effect of NO in rats in the present study.
The MWT shows the hypertrophy and hyperplasia of smooth muscle cells. One study has suggested that pulmonary artery smooth muscle hypertrophy and hyperplasia are associated with pulmonary vasoconstriction 1. New muscularisation of normally nonmuscular peripheral arteries shows that pericytes and intermediate cells differentiate into mature smooth muscle cells. The contractile ability to extrinsic vasoconstrictors in these newly muscularised arteries has not been studied extensively. Davies et al. 14 reported that the response to vasoconstrictor in newly muscularised arteries is reduced compared with normal peripheral arteries of the same size. Since NO-induced reduction in mPAP is positively correlated with the level of abnormal muscularisation of peripheral pulmonary arteries, newly muscularised arteries would have intrinsic vascular tone and thus, the total vasoconstrictive area would increase with the level of extension of smooth muscle into the peripheral pulmonary artery. Abnormal PAP correlates best with abnormal extension of muscle into peripheral arteries 8, which is consistent with the present findings. A new finding is that the degree of abnormal muscularisation of peripheral arteries is also significantly correlated with inhaled NO-induced absolute reduction in mPAP.
An increase in reactivity to NO in this model would be best assessed by the per cent decrease in pulmonary vascular resistance (PVR). However, as PVR was not measured and because it was assumed that the cardiac output remained unaffected, the reactivity was assessed by the per cent decrease in PAP rather than by the absolute change in PAP with NO. It was concluded that abnormal extension of smooth muscle to peripheral arteries did not increase the reactivity of the pulmonary arteries to NO. Many studies show a decrease in endothelium-dependent relaxation and in endothelium-independent relaxation in the pulmonary arteries of chronically hypoxic rats 15. Conversely, Dinh-Xuan et al. 16 and Orton et al. 17 demonstrated that endothelium-independent vasodilator response to sodium nitroprusside was unaltered.
Since abnormally muscular pulmonary vasculature might have a heightened reactivity 18, this suggested that the per cent reduction in mPAP due to NO inhalation would increase with the increase in severity in vascular changes. However, this was not the case in the present study. Under unstimulated conditions, hypertensive pulmonary vasculature might have a similar baseline vascular tone regardless of the severity of vascular changes, leading to similar per cent reductions in mPAP due to NO inhalation. Because of the similar per cent reductions at each concentration of NO, the higher the baseline mPAP, the greater the absolute value of the reduction in mPAP was. Although absolute active force-generating ability is increased due to the increase in the amount of smooth muscle cells, contractile force per cross-sectional area is reduced in hypertensive pulmonary arteries 19.
It was estimated that less NO-induced response suggests less severe vascular changes in the chronic hypoxic PH. However, this might not be the case in the clinical situation of hypertensive pulmonary vascular disease with intimal changes that show a high grade of severity in hypertensive pulmonary vascular disease. The present model does not develop intimal cellular and fibrotic proliferation. Once intimal changes develop, vascular responses to vasodilator start to decrease. The area of media was inversely related to the area of the intima, suggesting that medial wall thickness regresses despite progression of PH. Therefore, one weakness of this study was that the results applied to a very selective model, which were difficult to extend to clinical observations. Failure of inhaled NO to reduce PAP in a given patient with PH may not mean that pulmonary vascular remodelling is low in that particular case. Thus, high baseline PAP and a small response to inhaled NO might suggest fixed vascular changes, such as cellular and fibrous intimal proliferation. High baseline PAP and a good response to inhaled NO might suggest vascular lesions without intimal changes. In biopsy lung specimens from patients with PPH, the greater the area of pulmonary artery media, the greater the changes in PAP induced by intravenous or oral vasodilator drugs 20.
The reduction of mPAP during NO inhalation was correlated with the level of mPAP without NO in ARDS 12, 13, 21, chronic obstructive pulmonary disease 22 and congenital heart disease 18, but not in PPH 3 and another group of ARDS 5. The degree of response to inhaled NO was quite variable 1. Although pulmonary vascular response to inhaled NO is probably more complicated than a simple dependency upon the degree of muscularisation, one possible explanation might be the different degree of vascular remodelling among patients.
Nitric oxide inhalation is used for reducing pulmonary hypertension and improving oxygenation. In addition to treatment, nitric oxide inhalation is used in preoperative assessment at cardiac catheterisation to identify patients with a critically-limited and restricted pulmonary vascular bed 18. Since acute responses to nitric oxide in primary pulmonary hypertension are similar to those of vasodilators, such as prostacyclin, the response to nitric oxide inhalation might also be used to predict the effect of oral administration of these drugs 3. The present study showed that in a selective model of chronic hypoxic pulmonary hypertension in rats, the severity of pulmonary vascular remodelling might partly determine the magnitude of nitric-oxide induced reduction in mean pulmonary artery pressure.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
B. H. Jiang, J. Maruyama, A. Yokochi, M. Iwasaki, H. Amano, Y. Mitani, and K. Maruyama Prolonged Nitric Oxide Inhalation Fails to Regress Hypoxic Vascular Remodeling in Rat Lung Chest, June 1, 2004; 125(6): 2247 - 2252. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |